<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01602861</url>
  </required_header>
  <id_info>
    <org_study_id>Eudra CT: 2011-002243-98</org_study_id>
    <nct_id>NCT01602861</nct_id>
  </id_info>
  <brief_title>The Effects of Spironolactone on Calcineurin Inhibitor Induced Nephrotoxicity</brief_title>
  <acronym>SPIREN</acronym>
  <official_title>The Effects of Spironolactone on Calcineurin Inhibitor Induced Nephrotoxicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fredericia Hosptial</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether the diuretic drug spironolactone can prevent&#xD;
      chronic damage to transplanted kidneys caused by the medication that prevents rejection.&#xD;
&#xD;
      Spironolactone prevents the effects of the hormone aldosterone. Aldosterone is suspected of&#xD;
      being involved in the processes leading to chronic rejection of transplanted kidneys. Hence,&#xD;
      by blocking the effects of aldosterone we hope to be able to prevent loss of kidney function&#xD;
      in transplant patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AIM: The purpose of this study is to assess whether spironolactone can prevent the formation&#xD;
      of fibrosis in transplanted kidneys.&#xD;
&#xD;
      BACKGROUND: Calcineurin inhibitors (CNI) are one of the cornerstones of immunosuppressive&#xD;
      therapy after kidney transplantation. The introduction of CNI has caused a significant&#xD;
      decrease in acute rejections. However, CNI also have known side effects. These include the&#xD;
      formation of tubulointerstitial fibrosis in the transplanted kidney, contributing over time&#xD;
      to impaired kidney function and reduced graft survival.&#xD;
&#xD;
      The mineralocorticoid aldosterone may be involved in the development of renal fibrosis.&#xD;
      Recent observations suggest that aldosterone plays a central role in the pathogenesis of CNI&#xD;
      nephrotoxicity and that the mineralocorticoid-receptor-blocker spironolactone could be a&#xD;
      useful agent to prevent it.&#xD;
&#xD;
      METHODS: This study is a randomized, placebo-controlled, double-blind study in which 170&#xD;
      renal transplant patients will be recruited from two nephrological departments in Southern&#xD;
      Denmark. Patients will be randomized to three years of treatment with either spironolactone&#xD;
      or placebo added to the standard immunosuppressive treatment. Renal graft biopsies, various&#xD;
      molecular tests of tissue, blood and urine, chrome-EDTA clearance, 24-hour bloodpressure&#xD;
      measurement and blood samples will be performed at inclusion, after 1 year, 2 years and upon&#xD;
      completion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">April 2021</completion_date>
  <primary_completion_date type="Actual">April 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Cr EDTA clearance</measure>
    <time_frame>0, 1 year, 2 years, 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduced urine protein levels (change from baseline)</measure>
    <time_frame>0, 1 year, 2 years, 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduced fibrosis (change from baseline)</measure>
    <time_frame>0, 2 years</time_frame>
    <description>Verified by graft biopsies and immuno histochemistry. Newly transplanted patients will be subjected to additional biopsies 3 months and 1 year after inclusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduced blood pressure (change from baseline)</measure>
    <time_frame>0, 1 year, 2 years, 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular events</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">188</enrollment>
  <condition>Disorder Related to Renal Transplantation</condition>
  <arm_group>
    <arm_group_label>Spironolactone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>One tablet per day (25 mg Spironolactone/placebo) for the first three months. Subsequently dosage is increased to two tablets per day (50 mg Spironolactone/placebo) for the rest of the study.&#xD;
In case of hyperkaliemia (&gt;5,5 mmol/L) or intolerable side effects dosage will be reduced to one tablet per day (25 mg Spironolactone/placebo).</description>
    <arm_group_label>Spironolactone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 18 years&#xD;
&#xD;
          2. Proteinuria &lt; 3 g/24 hours&#xD;
&#xD;
          3. Creatinine clearance ≥ 30 mL/min&#xD;
&#xD;
          4. S-Potassium &lt; 5,5 mmol/L&#xD;
&#xD;
          5. Negative pregnancy test at the inclusion and anticonception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Intolerance to spironolactone&#xD;
&#xD;
          2. Creatinine clearance &lt; 30 ml/min&#xD;
&#xD;
          3. S-Potassium ≥ 5,5 mmol/L&#xD;
&#xD;
          4. Resin or digoxine treatment&#xD;
&#xD;
          5. Pregnancy or planned pregnancy&#xD;
&#xD;
          6. Relevant organic, systemic or mental illness&#xD;
&#xD;
          7. Anticipation of lack of compliance or understanding the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claus Bistrup, MD, ph.d.</last_name>
    <role>Study Director</role>
    <affiliation>Dep. of Nephrology, Odense University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 17, 2012</study_first_submitted>
  <study_first_submitted_qc>May 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2012</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Line Aas Mortensen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Fibrosis</keyword>
  <keyword>calcineurin inhibitor</keyword>
  <keyword>kidney transplant</keyword>
  <keyword>chronic rejection</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

